Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)

[1]  V. Brusasco,et al.  The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine) , 2014, Multidisciplinary Respiratory Medicine.

[2]  C F Donner,et al.  The clinical and integrated management of COPD. , 2014, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[3]  Alan D. Lopez,et al.  Measuring the global burden of disease. , 2013, The New England journal of medicine.

[4]  B. Yawn,et al.  Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis , 2013, International journal of chronic obstructive pulmonary disease.

[5]  C. Janson,et al.  Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study , 2013, Journal of internal medicine.

[6]  A. Anzueto,et al.  Number needed to treat in COPD: exacerbations versus pneumonias , 2013, Thorax.

[7]  E. Bateman,et al.  Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.

[8]  D. Price,et al.  Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[9]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[10]  Joan B. Soriano,et al.  Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice , 2012, European Respiratory Journal.

[11]  T. Seemungal,et al.  The role of bronchodilator treatment in the prevention of exacerbations of COPD , 2012, European Respiratory Journal.

[12]  A. Corrado,et al.  How far is real life from COPD therapy guidelines? An Italian observational study. , 2012, Respiratory medicine.

[13]  E. Bateman,et al.  Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison , 2012, Thorax.

[14]  Stephanie J. C. Taylor,et al.  Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology , 2011, Respiratory research.

[15]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society , 2011, Annals of Internal Medicine.

[16]  P. Enright,et al.  Counterpoint: should we abandon FEV₁/FVC < 0.70 to detect airway obstruction? Yes. , 2010, Chest.

[17]  Mm Jones.  Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care , 2010 .

[18]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[19]  D. Sin,et al.  Steroids in COPD: still up in the air? , 2010, European Respiratory Journal.

[20]  A. Leonard,et al.  Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD , 2010, International journal of chronic obstructive pulmonary disease.

[21]  A. Aggarwal,et al.  Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. , 2010, Chest.

[22]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[23]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[24]  P. Laveneziana,et al.  Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[25]  J. Wedzicha,et al.  Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial , 2007, Respiratory research.

[26]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians , 2007, Annals of Internal Medicine.

[27]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[28]  P. Calverley,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[29]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[30]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[31]  D. Postma,et al.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial , 2005, Thorax.

[32]  D. Forman,et al.  Delays in managing lung cancer. , 2004, Thorax.

[33]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[34]  N. Roche,et al.  Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease , 2001, European Respiratory Journal.

[35]  C. Sherman,et al.  Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. , 2001, American journal of respiratory and critical care medicine.

[36]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[37]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[38]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[39]  B. C. V. Zomeren,et al.  REPORT WORKING PARTY: STANDARDIZATION OF LUNG FUNCTION TESTS , 1983 .